2020
Incidence and Presentation of Sarcoidosis With and Without HIV Infection
Hanberg JS, Akgün K, Hsieh E, Fraenkel L, Justice A. Incidence and Presentation of Sarcoidosis With and Without HIV Infection. Open Forum Infectious Diseases 2020, 7: ofaa441. PMID: 33123611, PMCID: PMC7576681, DOI: 10.1093/ofid/ofaa441.Peer-Reviewed Original ResearchVeterans Aging Cohort StudyIncident sarcoidosisCD4 countCohort studyMedian CD4 countPresentation of sarcoidosisHIV-negative controlsAging Cohort StudyDiagnosis of sarcoidosisDevelopment of sarcoidosisHIV-1 RNAProspective observational analysisTreatment of sarcoidosisLongitudinal cohort studyIncidence of sarcoidosisRisk of sarcoidosisOral glucocorticoidsUninfected veteransUnsuppressed viremiaChart reviewOrgan involvementHIV infectionPersistent viremiaViral loadCase report
2016
D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events
Freiberg MS, Bebu I, Tracy R, So-Armah K, Okulicz J, Ganesan A, Armstrong A, O’Bryan T, Rimland D, Justice AC, Agan BK, . D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLOS ONE 2016, 11: e0152588. PMID: 27088215, PMCID: PMC4835105, DOI: 10.1371/journal.pone.0152588.Peer-Reviewed Original ResearchConceptsNon-AIDS diseasesNon-AIDS eventsD-dimer levelsHIV viral suppressionART initiationAntiretroviral therapyViral suppressionD-dimerInterleukin-6Time pointsUS Military HIV Natural History StudyMulticenter observational cohortMedian CD4 countIL-6 levelsMean percent increaseActive duty military personnelNatural history studiesDuty military personnelCD4 countHIV seroconversionHIV levelsMedian durationObservational cohortMedian timeExcess risk
2015
Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study
Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA, Collaboration H. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. The Lancet HIV 2015, 2: e335-e343. PMID: 26423376, PMCID: PMC4643831, DOI: 10.1016/s2352-3018(15)00108-3.Peer-Reviewed Original ResearchConceptsNeed of ARTHIV RNA viral loadCD4 countAntiretroviral therapyHIV-positive individualsMean survival timeImmediate initiationHIV diagnosisCohort studyViral loadRelative riskHigh-income countriesProportion of individualsSurvival timeInitiation of ARTART initiation strategiesImmediate antiretroviral therapyLow CD4 countMedian CD4 countObservational cohort studyAIDS-free survivalHIV-1 infectionDiagnosis of HIVViral load measurementsHIV-CAUSAL Collaboration
2010
CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?
Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Eron JJ, Napravnik S, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Goedert JJ, McKaig RG, Thorne J, Rachlis A, Moore RD, Justice AC, for the North American AIDS Cohort Collaboration on Research and Design. CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation? AIDS Research And Therapy 2010, 7: 45. PMID: 21159161, PMCID: PMC3022663, DOI: 10.1186/1742-6405-7-45.Peer-Reviewed Original ResearchCD4 countHIV careRace/ethnicityFirst presentationNorth American AIDS Cohort CollaborationHIV transmission risk groupAge groupsAdvanced HIV diseaseHIV testing effortsLow CD4 countTransmission risk groupsMean CD4 countMedian CD4 countHIV transmission riskCohort CollaborationHIV diseaseInitial presentationRisk groupsClinical cohortProportion of individualsTransmission riskOlder individualsYoung adultsCohortYoung individualsLate Presentation for Human Immunodeficiency Virus Care in the United States and Canada
Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Kushel M, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD, Research and Design N. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. Clinical Infectious Diseases 2010, 50: 1512-1520. PMID: 20415573, PMCID: PMC2862849, DOI: 10.1086/652650.Peer-Reviewed Original ResearchConceptsMean CD4 countPercentage of patientsHIV transmission riskCD4 countHIV careFirst presentationTransmission riskCells/North American AIDS Cohort CollaborationHuman immunodeficiency virus (HIV) careHuman immunodeficiency virus (HIV) servicesHeterosexual transmission riskMedian CD4 countEarly HIV diagnosisT-lymphocyte countsHIV RNA measurementsHistory of AIDSRace/ethnicityAntiretroviral exposureCohort CollaborationHIV diagnosisLymphocyte countInitial presentationMedian ageLate presentation
2009
Incidence of Non-AIDS-Defining Malignancies in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression
Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of Non-AIDS-Defining Malignancies in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 52: 203-208. PMID: 19617846, PMCID: PMC2814969, DOI: 10.1097/qai.0b013e3181b033ab.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapy (HAART) eraAntiretroviral therapy eraIncidence rate ratiosCD4 countTherapy eraAnal cancerLow CD4 countHigher CD4 countsMedian CD4 countImpact of immunosuppressionRate ratioCohort of veteransNon-AIDSNoninfected patientsHAART eraUninfected patientsHodgkin's lymphomaIncidence rateProstate cancerHIVPatientsCancerIndividual cancersMalignancyIncidence
2001
Veterans aging cohort three-site study (VACS 3) overview and description
Smola S, Justice AC, Wagner J, Rabeneck L, Weissman S, Rodriguez-Barradas M, Team F. Veterans aging cohort three-site study (VACS 3) overview and description. Journal Of Clinical Epidemiology 2001, 54: s61-s76. PMID: 11750212, DOI: 10.1016/s0895-4356(01)00448-6.Peer-Reviewed Original ResearchConceptsHIV infectionProvider surveyVeterans Affairs Medical CenterMedian CD4 countVeterans Aging CohortMedian viral loadUse of cigarettesFuture clinical interventionsInfluence of ageCD4 countAntiretroviral medicationsComorbid diseasesDisease clinicViral loadPoor outcomeMean ageThree-site studyAlternative therapiesAge-related differencesCopies/Medical CenterHIVAging CohortTwelve-monthClinical interventions